We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ezose Sciences Forms Agreement with Kyowa Hakko Kirin
News

Ezose Sciences Forms Agreement with Kyowa Hakko Kirin

Ezose Sciences Forms Agreement with Kyowa Hakko Kirin
News

Ezose Sciences Forms Agreement with Kyowa Hakko Kirin

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ezose Sciences Forms Agreement with Kyowa Hakko Kirin"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under terms of the research agreement, Kyowa Hakko Kirin will fund several glycanbiomarker and other discovery projects, with an option for further research and development. Other details of the agreement were not disclosed. 

“We look forward to putting our unique glycan-analysis capabilities to the service of the specific research interests of Kyowa Hakko Kirin,” said Hidehisa Asada, Ph.D., Vice President, Research & Development of Ezose. “As the structure of our collaboration anticipates, the research will seek new discoveries that enable novel therapeutic strategies and sustain the flow of new products to market.” 

About Glycomics 
Glycomics is the study of glycans, the sugar chains that during the biochemical process known as glycosylation become attached to many proteins expressed by human cells. The particular glycans involved may crucially determine the function of the resulting glycoprotein and its role in health and disease. 

Glycomics is a natural complement to genomics and proteomics, but it has traditionally been hindered by the lack of practical high-throughput and quantitative technologies. Ezose’s proprietary GlycanMap® platform addresses this need by combining, in an automated 96-well format, high-throughput glycan enrichment with specialized MALDITOF mass spectrometry and custom bioinformatics to both structurally identify and quantitate glycans present in complex biological samples. Such glycans can serve as novel biomarkers to aid in the development of drugs, vaccines, and diagnostic tests, including companion diagnostics. In addition, glycomics holds potential for uncovering new therapeutic targets and mechanisms and for guiding the development and manufacture of glycosylated biologics and biosimilars. 

Advertisement